Quinacrine (DrugBank: Quinacrine)
1 disease| 告示番号 | 疾患名（ページ内リンク） | 臨床試験数 |
|---|---|---|
| 23 | プリオン病 | 2 |
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT00183092 (ClinicalTrials.gov) | April 2005 | 14/9/2005 | CJD (Creutzfeldt-Jakob Disease) Quinacrine Study | Novel Therapeutics For Prion Diseases: A Randomized, Double-blinded, Placebo-controlled Study of the Efficacy of Quinacrine in the Treatment of Sporadic Creutzfeldt-Jakob Disease | Creutzfeldt-Jakob Disease | Drug: Quinacrine;Drug: Placebo | University of California, San Francisco | National Institute on Aging (NIA) | Completed | 18 Years | N/A | All | 69 | Phase 2 | United States |
| 2 | NCT00104663 (ClinicalTrials.gov) | June 2004 | 3/3/2005 | PRION-1: Quinacrine for Human Prion Disease | PRION-1: Quinacrine for Human Prion Disease. A Partially Randomized Patient Preference Trial to Evaluate the Activity and Safety of Quinacrine in Human Prion Disease | Prion Disease | Drug: Quinacrine | Medical Research Council | NULL | Completed | 12 Years | N/A | Both | 160 | N/A | United Kingdom |